Treatment of Hepatitis C in Special Population

Treatment of Hepatitis C in Special Populations: Comprehensive Summary

1. Main Clinical Topics Discussed

This lecture addresses the management of Hepatitis C Virus (HCV) infection in several special patient populations, including those with chronic kidney disease (CKD)/end-stage renal disease (ESRD), kidney transplant recipients, decompensated cirrhosis, HCV/HIV co-infection, hepatitis B co-infection/reactivation, acute HCV in the context of the opioid epidemic, organ transplantation using HCV-positive donors, and pediatric/pregnant patients.

2. Key Learning Points, Guidelines, and Recommendations

General HCV Treatment Landscape

• Current direct-acting antiviral (DAA) regimens are all-oral, pan-genotypic, short-course (8–16 weeks), and largely free of significant side effects
• Overall cure rates (sustained virologic response, SVR) approach 95–99% across all genotypes
• Genotype 3 remains slightly less responsive, with cure rates in the mid-90s
• Salvage therapy (sofosbuvir/velpatasvir/voxilaprevir – "SOF/VEL/VOX box") achieves SVR rates of 95–98% in patients who fail first-line therapy
• Combined first-line and salvage therapy yields an overall cure rate of approximately 99% for all comers

HCV in Renal Disease and Kidney Transplantation

• HCV prevalence in hemodialysis patients: ~4% in the US, ~20% in the Middle East
• All currently available DAA regimens can be used safely in CKD stages 3, 4, and 5, including patients on hemodialysis — without dose reduction
• Sofosbuvir-based regimens, previously avoided due to renal excretion of metabolites, are now confirmed safe in patients with GFR <30 and those on hemodialysis
• SVR rates in CKD/ESRD patients are equivalent to those in patients with normal renal function
• Key drug interaction caveat: cyclosporine (and other immunosuppressants) may interact with certain DAA regimens; requires close monitoring
• AASLD/IDSA guidelines recommend glecaprevir/pibrentasvir (G/P) or sofosbuvir-based regimens for treatment-naïve, DAA-experienced, and post-transplant patients of any genotype, with or without compensated cirrhosis

HCV-Positive Organ Transplantation Strategy

• Average kidney transplant wait time in the US: 5–6 years
• Using HCV-positive kidneys in both HCV-positive and HCV-negative recipients significantly reduces transplant wait times
• Current US practice trend: defer HCV treatment until post-transplant, then initiate DAA therapy within days of transplantation
• Post-transplant DAA treatment achieves SVR rates of ~99%

Arguments For and Against Pre-Transplant HCV Treatment

HCV and HIV Co-infection

• No longer considered a "special population" — DAA cure rates in HIV/HCV co-infected patients are equivalent to those in HCV-monoinfected patients

3. Specific Clinical Data and Study Results Cited

• Glecaprevir/pibrentasvir in CKD Stage 4–5 (EXPEDITION-4 trial, presented by Dr. David Roth, University of Miami):

- Genotype 1 patients with Stage 4 and 5 CKD

- Modified full analysis set SVR: 99%

- Intention-to-treat (full analysis) SVR: 94%